Given that MT-III can bind copper ions [85], the down-regulation of MT-III in a patient as well as a transgenic mouse model of Alzheimer’s disease has been proposed to alter copper homeostasis in the brain and then lead to extracellular amyloid pathology [86,87]. Here, MT3 is linked to amyloidosis.